Sinopharm is jointly owned by China National Pharmaceutical Group and Shanghai Fosun Pharmaceutical. Directly controlled by the state-owned Assets Supervision and Administration Commission of the State Council, it is recognized as China's largest and only nationwide distributor and wholesaler.

"The largest medical and healthcare group in China grew to $25.8 billion last year, registering a 25 percent growth."

The reforms in the healthcare sector over the last three years have changed the face of this company. They found a market that is advancing and is easy to penetrate and dominate - thanks to Sinopharm's strong and wide countrywide network.

Establishing a steady growth over the years, the company increased its market share and profits this year and its overall revenue grew from $21.73 in 2012-13 to $25.89 billion in 2013-14.

One of the biggest advents made by this company in 2013 included collaborating with Japan's Mitsubishi Corporation. Both the pioneers teamed up to form a medical supplies distributor and slash the rising cost of healthcare in Asia's biggest economy.

In spite of unwanted controversies, Sinopharm saw its first-quarter profit jump 31 percent to $112.19 million (701.5 million yuan) on Chinese demand for healthcare products. Further, Hutchison China MediTech (Chi-Med) and Sinopharm Group received regulatory approval to form a drug distribution joint venture-Hutchison Whampoa Sinopharm Pharmaceuticals (Shanghai) Company. Chi-Med is investing $9.8 million to buy majority control (51 percent) of a Sinopharm subsidiary, HuYong Pharmaceutical (Shanghai).